This news has moved the needle a little....but nothing big. Great news that the company can get to work on dosing American patients for the BETonMACE trial, but we still don't know how they're gonna pay for it....or for BETonCKD, or Fabry or, or, or....
Answer that question and we're back over $2 imo and beyond....